Style | Citing Format |
---|---|
MLA | S Mashayekhi SAMINE, et al.. "Ferroptosis As a Therapeutic Target in Glioblastoma: Mechanisms and Emerging Strategies." Molecular Therapy Nucleic Acids, vol. 36, no. 3, 2025, pp. -. |
APA | S Mashayekhi SAMINE, H Majedi HOSSEIN, Ar Dehpour Ahmad REZA, S Dehghan SAMANEH, M Jafarian MARYAM, Mr Hadjighasem Mahmoudreza REZA, S Hosseindoost SAEREH (2025). Ferroptosis As a Therapeutic Target in Glioblastoma: Mechanisms and Emerging Strategies. Molecular Therapy Nucleic Acids, 36(3), -. |
Chicago | S Mashayekhi SAMINE, H Majedi HOSSEIN, Ar Dehpour Ahmad REZA, S Dehghan SAMANEH, M Jafarian MARYAM, Mr Hadjighasem Mahmoudreza REZA, S Hosseindoost SAEREH. "Ferroptosis As a Therapeutic Target in Glioblastoma: Mechanisms and Emerging Strategies." Molecular Therapy Nucleic Acids 36, no. 3 (2025): -. |
Harvard | S Mashayekhi SAMINE et al. (2025) 'Ferroptosis As a Therapeutic Target in Glioblastoma: Mechanisms and Emerging Strategies', Molecular Therapy Nucleic Acids, 36(3), pp. -. |
Vancouver | S Mashayekhi SAMINE, H Majedi HOSSEIN, Ar Dehpour Ahmad REZA, S Dehghan SAMANEH, M Jafarian MARYAM, Mr Hadjighasem Mahmoudreza REZA, et al.. Ferroptosis As a Therapeutic Target in Glioblastoma: Mechanisms and Emerging Strategies. Molecular Therapy Nucleic Acids. 2025;36(3):-. |
BibTex | @article{ author = {S Mashayekhi SAMINE and H Majedi HOSSEIN and Ar Dehpour Ahmad REZA and S Dehghan SAMANEH and M Jafarian MARYAM and Mr Hadjighasem Mahmoudreza REZA and S Hosseindoost SAEREH}, title = {Ferroptosis As a Therapeutic Target in Glioblastoma: Mechanisms and Emerging Strategies}, journal = {Molecular Therapy Nucleic Acids}, volume = {36}, number = {3}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - S Mashayekhi SAMINE AU - H Majedi HOSSEIN AU - Ar Dehpour Ahmad REZA AU - S Dehghan SAMANEH AU - M Jafarian MARYAM AU - Mr Hadjighasem Mahmoudreza REZA AU - S Hosseindoost SAEREH TI - Ferroptosis As a Therapeutic Target in Glioblastoma: Mechanisms and Emerging Strategies JO - Molecular Therapy Nucleic Acids VL - 36 IS - 3 SP - EP - PY - 2025 ER - |